AstronauTx

AstronauTx is a clinical-stage UK biotech developing oral small molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders.

The company's approach targets astrocytes, brain support cells whose dysregulated inflammatory activity contributes to neurodegeneration, aiming to restore normal physiology rather than directly target amyloid or tau pathology.

AstronauTx has an ongoing drug discovery collaboration with the Alzheimer's Research UK UCL Drug Discovery Institute and raised £48 million in Series A financing in 2023.